Background 35 The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third 36 zoonotic CoV has raised great public health concern. The demand for rapid and accurate 37 diagnosis of this novel pathogen brought significant clinical and technological challenges. 38 Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR 39 (RT-PCR) are the most widely used molecular diagnostics for 2019-nCoV. 40 Methods 41 2019-nCoV infections were confirmed in 52 specimens by mNGS. Genomic information was 42 analyzed and used for the design and development of an isothermal, CRISPR-based 43 diagnostic for the novel virus. The diagnostic performance of CRISPR-nCoV was assessed 44 and also compared across three technology platforms (mNGS, RT-PCR and CRISPR) 45 Results 46 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared 47 RNA was observed in clinical specimens. CRISPR-nCoV demonstrated a near single-copy 49 sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR.
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INTRODUCTION
Although CRISPR/Cas has been widely used as a programmable tool for gene editing since 75 2013, the collateral, promiscuous cleavage activities of a unique group of Cas nucleases only 76 discovered recently and harnessed for in vitro nucleic acid detection. [15] [16] [17] [18] [19] 77 Here, to address this question and the expanding clinical needs, we developed CRISPR-nCoV, 78 a rapid assay for 2019-nCoV detection, and compared the diagnostic performance among 79 three different technological platforms: metagenomic sequencing, RT-PCR and CRISPR. To 80 our knowledge, this is the first report on cross-platform comparison and the evaluation of an 81 isothermal, CRISPR-based assay for 2019-nCoV that's rapid, sensitive and with low 82 instrument requirement. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
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Evaluation of limit of detection (LoD)
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The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint For the evaluation of LoD by the number of DNA copies, DNA of the 2019-nCoV plasmid 155 was purified and the concentration was determined by a Qubit (Thermo Fisher, 156 Massachusetts). The copy number concentration was then calculated based the weight and the 157 length of fragment. Serial dilution with nuclease-free water was done to achieve desired 158 concentrations. 2.5μl of extracted DNA at each titer was used as templates. Ten replicates 159 were performed at each data point near detection limit. In order to develop a targeted assay for the novel virus, we obtained total RNA samples 170 from 61 cases suspected for 2019-nCoV infection and subjected them to metagenomic 171 next-generation sequencing (mNGS), the method by which this novel virus was initially 172 identified. Briefly, RNA was reverse-transcribed into cDNA to prepare for the sequencing 173 library. Each library was subjected to high-throughput sequencing. Sequenced reads were 174 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint aligned to a curated database for taxonomic classification and identification of 2019-nCoV 175 genomic sequences. 176 Among the 61 suspected nCoV specimens, we were able to confirm 52 cases with read 177 numbers mapping to the novel virus across 6 orders of magnitudes (median read of 1,484, 178 from 2 to 19,016,501). The median genome coverage and sequencing depth was 46.8%
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(2.8%-100%) and 12.0× (1.0×-7870.1×), respectively ( Figure 1A) . These findings indicate a 180 high degree of variation in viral loads of nCoV infections. As shown in the phylogenetic trees, 181 2019-nCoV genome identified in our specimens were highly conserved with the Wuhan 182 strain and closest to SARS-CoV ( Figure 1B) .
183
With these genomic information, we aimed to identify target regions of 2019-nCoV by 191 We seek to develop a rapid, highly sensitive and simple-to-use assay by taking advantage 192 of both the polymerase-mediated DNA amplification by RPA and the CRISPR/Cas-mediated 193 enzymatic signal amplification for improved sensitivity (Figure 2A) . Moreover, the 194 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Development of CRISPR-nCoV
The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint isothermal nature of such an assay abolished the demand for sophiscated instruments such as 195 thermal cyclers as for PCR-based assays. 196 Based on the three potential target sequences we identified, multiple sets of RPA primers 197 and CRISPR gRNAs were designed and screened. Among these, the set that targeted Orf1ab 198 showed the best overall performance of sensitivity and specificity, and therefore, was used to 199 develop CRISPR-nCoV in this study for further evaluation (data not shown). 200 We then sought to determine its analytical sensitivity by serial dilution at various 201 concentrations. As shown in Figure 2B , CRISPR-nCoV consistently detected 7.5 copies of 202 2019-nCoV in all 10 replicates, 2.5 copies in 6 out of 10 , and 1.25 copies in 2 out of 10 runs. 203 These data indicate that CRISPR-nCoV had a near single-copy sensitivity. To confirm its the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020. 02.22.20025460 doi: medRxiv preprint We further set out to compare the diagnostic performances among mNGS, RT-PCR and the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint opportunity to take advantage of both the sensitivity of an isothermal assay and the specificity 279 of the CRISPR system. [21] As we demonstrated in this study, CRISPR-nCoV was able to 280 deliver comparable sensitivity and specificity as mNGS within as short as 40 minutes.
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As a result of the rapid outbreak, the targeted assays (PCR and CRISPR) were designed 282 and developed based on limited genetic information on 2019-nCoV. Cautions should be taken 283 that certain unknown genomic variations may produce critical impact on the assay efficiency. 
